-
1.
公开(公告)号:US20100173913A1
公开(公告)日:2010-07-08
申请号:US12724203
申请日:2010-03-15
申请人: Eddy Jean Edgard Freyne , Marc Willems , Pierre Henri Storck , Virginie Sophie Poncelet , Kristof Van Emelen , Peter Jacobus Johannes Antonius Buijnsters , Werner Constant Johan Embrechts , Timothy Pietro Suren Perera
发明人: Eddy Jean Edgard Freyne , Marc Willems , Pierre Henri Storck , Virginie Sophie Poncelet , Kristof Van Emelen , Peter Jacobus Johannes Antonius Buijnsters , Werner Constant Johan Embrechts , Timothy Pietro Suren Perera
IPC分类号: A61K31/529 , C07D498/18 , A61P35/00 , C07D487/18
CPC分类号: C07D498/16 , C07D471/04 , C07D487/04 , C07D487/16 , C07D487/22
摘要: The present invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein a1-a2=a3-a4 represents a divalent radical selected from N—CH═CH—CH, N—CH═N—CH or CH—CH═N—CH; Z represents NH; Y represents —C3-9alkyl-, —C1-5alkyl-NR13—C1-5alkyl-, —C1-6alkyl-NH—CO— or —CO—NH—C1-6alkyl-; X1 represents —O— or —NR11—; X2 represents —C1-2alkyl-, —O—C1-2alkyl, —O— or —O—CH2—; R1 represents hydrogen or halo; R2 represents hydrogen, cyano, halo, hydroxycarbonyl-, C1-4alkyloxycarbonyl-, Het16-carbonyl- or Ar5; R3 represents hydrogen; R4 represents hydroxy, C1-4alkyloxy-, Ar4—C1-4alkyloxy or R4 represents C1-4alkyloxy substituted with one or where possible two or more substituents selected from C1-4alkyloxy- or Het2-; R11 represents hydrogen; R12 represents hydrogen, C1-4alkyl- or C1-4alkyl-oxy-carbonyl-; R13 represents Het14-C1-4alkyl, in particular morpholinyl-C1-4alkyl; Het2 represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with C1-4alkyl-, preferably methyl; Het14 represents morpholinyl; Het16 represents a heterocycle selected from morpholinyl or pyrrolidinyl; Ar4 represents phenyl; Ar5 represents phenyl optionally substituted with cyano.
摘要翻译: 本发明涉及N-氧化物形式的化合物,其药学上可接受的加成盐和立体化学异构体,其中a1-a2 = a3-a4表示选自N-CH = CH-CH,N- CH = N-CH或CH-CH = N-CH; Z表示NH; Y表示-C3-9烷基 - ,-C1-5烷基-NR13-C1-5烷基 - ,C1-6烷基-NH-CO-或-CO-NH-C1-6烷基 - ; X1表示-O-或-NR11-; X2表示-C1-2烷基 - , - O-C1-2烷基,-O-或-O-CH2-; R1表示氢或卤素; R 2表示氢,氰基,卤素,羟基羰基 - ,C 1-4烷氧基羰基 - ,Het 16 - 羰基 - 或Ar 5; R3表示氢; R 4表示羟基,C 1-4烷氧基 - ,Ar 4 -C 1-4烷氧基或R 4表示被一个或多个可能的两个或多个选自C 1-4烷氧基或Het 2-的取代基取代的C 1-4烷氧基; R11表示氢; R 12表示氢,C 1-4烷基 - 或C 1-4烷基 - 氧基 - 羰基 - ; R13表示Het14-C1-4烷基,特别是吗啉基-C 1-4烷基; Het2表示选自任选被C 1-4烷基,优选甲基取代的吗啉基或哌啶基的杂环; Het14代表吗啉基; Het16表示选自吗啉基或吡咯烷基的杂环; Ar4表示苯基; Ar 5表示任选被氰基取代的苯基。
-
2.
公开(公告)号:US08772272B2
公开(公告)日:2014-07-08
申请号:US12724203
申请日:2010-03-15
申请人: Eddy Jean Edgard Freyne , Marc Willems , Pierre Henri Storck , Virginie Sophie Poncelet , Kristof Van Emelen , Peter Jacobus Johnnes Antonius Buijnsters , Werner Constant Johan Embrechts , Timothy Pietro Suren Perera
发明人: Eddy Jean Edgard Freyne , Marc Willems , Pierre Henri Storck , Virginie Sophie Poncelet , Kristof Van Emelen , Peter Jacobus Johnnes Antonius Buijnsters , Werner Constant Johan Embrechts , Timothy Pietro Suren Perera
IPC分类号: A61K31/33 , A61K31/519 , C07D487/00 , C07D487/18
CPC分类号: C07D498/16 , C07D471/04 , C07D487/04 , C07D487/16 , C07D487/22
摘要: The present invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein a1-a2=a3-a4 represents a divalent radical selected from N—CH═CH—CH, N—CH═N—CH or CH—CH═N—CH; Z represents NH; Y represents —C3-9alkyl-, —C1-5alkyl-NR13—C1-5alkyl-, —C1-6alkyl-NH—CO— or —CO—NH—C1-6alkyl-; X1 represents —O— or —NR11—; X2 represents —C1-2alkyl-, —O—C1-2alkyl, —O— or —O—CH2—; R1 represents hydrogen or halo; R2 represents hydrogen, cyano, halo, hydroxycarbonyl-, C1-4alkyloxycarbonyl-, Het16-carbonyl- or Ar5; R3 represents hydrogen; R4 represents hydroxy, C1-4alkyloxy-, Ar4—C1-4alkyloxy or R4 represents C1-4alkyloxy substituted with one or where possible two or more substituents selected from C1-4alkyloxy- or Het2-; R11 represents hydrogen; R12 represents hydrogen, C1-4alkyl- or C1-4alkyl-oxy-carbonyl-; R13 represents Het14-C1-4alkyl, in particular morpholinyl-C1-4alkyl; Het2 represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with C1-4alkyl-, preferably methyl; Het14 represents morpholinyl; Het16 represents a heterocycle selected from morpholinyl or pyrrolidinyl; Ar4 represents phenyl; Ar5 represents phenyl optionally substituted with cyano.
摘要翻译: 本发明涉及N-氧化物形式的化合物,其药学上可接受的加成盐和立体化学异构体,其中a1-a2 = a3-a4表示选自N-CH = CH-CH,N- CH = N-CH或CH-CH = N-CH; Z表示NH; Y表示-C3-9烷基 - ,-C1-5烷基-NR13-C1-5烷基 - ,C1-6烷基-NH-CO-或-CO-NH-C1-6烷基 - ; X1表示-O-或-NR11-; X2表示-C1-2烷基 - , - O-C1-2烷基,-O-或-O-CH2-; R1表示氢或卤素; R 2表示氢,氰基,卤素,羟基羰基 - ,C 1-4烷氧基羰基 - ,Het 16 - 羰基 - 或Ar 5; R3表示氢; R 4表示羟基,C 1-4烷氧基 - ,Ar 4 -C 1-4烷氧基或R 4表示被一个或多个可能的两个或多个选自C 1-4烷氧基或Het 2-的取代基取代的C 1-4烷氧基; R11表示氢; R 12表示氢,C 1-4烷基 - 或C 1-4烷基 - 氧基 - 羰基 - ; R13表示Het14-C1-4烷基,特别是吗啉基-C 1-4烷基; Het2表示选自任选被C 1-4烷基,优选甲基取代的吗啉基或哌啶基的杂环; Het14代表吗啉基; Het16表示选自吗啉基或吡咯烷基的杂环; Ar4表示苯基; Ar 5表示任选被氰基取代的苯基。
-
3.
公开(公告)号:US07799772B2
公开(公告)日:2010-09-21
申请号:US10596512
申请日:2004-12-15
申请人: Eddy Jean Edgard Freyne , Pierre Henri Storck , Virginie Sophie Poncelet , Timothy Pietro Suren Perera
发明人: Eddy Jean Edgard Freyne , Pierre Henri Storck , Virginie Sophie Poncelet , Timothy Pietro Suren Perera
IPC分类号: A01N43/00 , A61K31/33 , C07D225/00 , C07D295/00
CPC分类号: C07D498/16 , C07D471/04 , C07D487/04 , C07D487/16 , C07D487/22
摘要: The present invention concerns the compounds of formula wherein a1-a2=a3-a4 represents a divalent radical selected from N—CH═CH—CH, N—CH═N—CH or CH—CH═N—CH; Z represents NH; Y represents —C3-9alkyl-, —C1-5alkyl-NR13—C1-5alkyl-, —C1-6alkyl-NH—CO— or —CO—NH—C1-6alkyl-; X1 represents —O— or —NR11—; X2 represents —C1-2alkyl-, —O—C1-2alkyl, —O— or —O—CH2—; R1 represents hydrogen or halo; R2 represents hydrogen, cyano, halo, hydroxycarbonyl-, C1-4alkyloxycarbonyl-, Het16-carbonyl- or Ar5; R3 represents hydrogen; R4 represents hydroxy, C1-4alkyloxy-, Ar4—C1-4alkyloxy or R4 represents C1-4alkyloxy substituted with one or where possible two or more substituents selected from C1-4alkyloxy- or Het2-; R11 represents hydrogen; R12 represents hydrogen, C1-4alkyl- or C1-4alkyl-oxy-carbonyl-; R13 represents Het14-C1-4alkyl, in particular morpholinyl-C1-4alkyl; Het2 represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with C1-4alkyl-, preferably methyl; Het14 represents morpholinyl; Het16 represents a heterocycle selected from morpholinyl or pyrrolidinyl; Ar4 represents phenyl; Ar5 represents phenyl optionally substituted with cyano.
摘要翻译: 本发明涉及下式的化合物:其中a 1-a 2 = a 3-a 4表示选自N-CH = CH,N-CH = N-CH或CH-CH = N-CH的二价基团; Z表示NH; Y表示-C3-9烷基 - ,-C1-5烷基-NR13-C1-5烷基 - ,C1-6烷基-NH-CO-或-CO-NH-C1-6烷基 - ; X1表示-O-或-NR11-; X2表示-C1-2烷基 - , - O-C1-2烷基,-O-或-O-CH2-; R1表示氢或卤素; R 2表示氢,氰基,卤素,羟基羰基 - ,C 1-4烷氧基羰基 - ,Het 16 - 羰基 - 或Ar 5; R3表示氢; R 4表示羟基,C 1-4烷氧基 - ,Ar 4 -C 1-4烷氧基或R 4表示被一个或多个可能的两个或多个选自C 1-4烷氧基或Het 2-的取代基取代的C 1-4烷氧基; R11表示氢; R 12表示氢,C 1-4烷基 - 或C 1-4烷基 - 氧基 - 羰基 - ; R13表示Het14-C1-4烷基,特别是吗啉基-C 1-4烷基; Het2表示选自任选被C 1-4烷基,优选甲基取代的吗啉基或哌啶基的杂环; Het14代表吗啉基; Het16表示选自吗啉基或吡咯烷基的杂环; Ar4表示苯基; Ar 5表示任选被氰基取代的苯基。
-
公开(公告)号:US20100152174A1
公开(公告)日:2010-06-17
申请号:US11720693
申请日:2005-12-08
申请人: Eddy Jean Edgard Freyne , Marc Willems , Peter Ten Holte , Alexandra Papanikos , Werner Constant John Embrechts , Pierre Henri Storck , Virginie Sophie Poncelet , Werner Constant Johan Embrechts , Pierre Henri Storck , Virginie Sophie Poncelet
发明人: Eddy Jean Edgard Freyne , Marc Willems , Peter Ten Holte , Alexandra Papanikos , Werner Constant John Embrechts , Pierre Henri Storck , Virginie Sophie Poncelet , Werner Constant Johan Embrechts , Pierre Henri Storck , Virginie Sophie Poncelet
IPC分类号: A61K31/541 , A61K31/5377 , A61K31/496 , A61K31/517 , C07D498/04 , A61P35/00
CPC分类号: C07D498/06 , C07D498/08
摘要: The present invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z represents NH; Y represents —C3-9alkyl-, —C1-5alkyl-NR13—C1-5alkyl-, —C1-5alkyl-NR14—CO—C1-5alkyl-, —C1-2alkyl-NR21—H2—CO—NH—C1-3alkyl- or —C1-2alkyl-NR23—CO—CR16R17—NH—; X1 represents O or —O—C1-2alkyl-; X2 represents a direct bond, C1-2alkyl, —CO—C1-2alkyl or NR12—C1-2alkyl; R1 represents hydrogen or halo; R2 represents halo, acetylene or Het1; R3 represents hydrogen or cyano; R4 represents Ar4—C1-4alkyloxy-, C1-4alkyloxy- or C1-4alkyloxy substituted with one or where possible two or more substituents selected from Het2, NR7R8, hydroxy and C1-4alkyloxy-C1-4alkyloxy-; R7 represents hydrogen or C1-4alkyl; R8 represents C1-4alkyl substituted with NR25R26 or C1-4alkylsulfonyl; R12 represents hydrogen or C1-4alkyl-; R13 represents Ar6-sulfonyl or C1-6alkyloxycarbonyl optionally substituted with phenyl; R16 and R17 represents hydrogen, C1-4alkyl or R16 and R17 taken together with the carbon atom to which they are attached from a C3-6cycloalkyl; R23 represents C1-4alkyl and R23 represents hydrogen when R16 and R17 taken together with the carbon atom to which they are attached from a C3-6cycloalkyl; R25, R26, R27 and R28 each independently represent hydrogen or C1-4alkylcarbonyl; Het1 represents 2-bora-1,3-dioxolanyl; Het represents piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl or 1,1-dioxothiomorpholinyl wherein said Het2 is optionally substituted with C1-4alkyloxycarbonyl or NR27R28—C1-4alkyl; Ar4 and Ar5 represents phenyl; Ar6 represents phenyl optionally substituted with nitro.
摘要翻译: 本发明涉及式(I)化合物,N-氧化物形式,其药学上可接受的加成盐和立体化学异构形式,其中Z表示NH; Y表示-C3-9烷基,-C1-5烷基-NR13-C1-5烷基,-C1-5烷基-NR14-CO-C1-5烷基,-C1-2烷基-NR21-H2-CO-NH-C1-3烷基 - 或-C1-2烷基-NR23-CO-CR16R17-NH-; X 1表示O或-O-C 1-2烷基 - ; X2表示直接键,C1-2烷基,-CO-C1-2烷基或NR12-C1-2烷基; R1表示氢或卤素; R2代表卤代,乙炔或Het1; R3表示氢或氰基; R 4表示被一个或多个可能的两个或多个选自Het 2,NR 7 R 8,羟基和C 1-4烷氧基-C 1-4烷氧基 - 的取代基取代的Ar 4 -C 1-4烷氧基 - ,C 1-4烷氧基 - 或C 1-4烷氧基。 R7代表氢或C1-4烷基; R8表示被NR25R26或C1-4烷基磺酰基取代的C1-4烷基; R 12表示氢或C 1-4烷基 - ; R 13表示Ar 6 - 磺酰基或任选被苯基取代的C 1-6烷氧基羰基; R 16和R 17表示氢,C 1-4烷基或R 16和R 17与它们与C 3-6环烷基连接的碳原子一起; 当R 16和R 17与C 3-6环烷基连接的碳原子一起时,R 23表示C 1-4烷基,R 23表示氢; R 25,R 26,R 27和R 28各自独立地表示氢或C 1-4烷基羰基; Het1代表2-硼-1,3-二氧戊环基; Het表示哌啶基,哌嗪基,吗啉基,硫代吗啉基或1,1-二氧代硫代吗啉基,其中所述Het2任选被C 1-4烷氧基羰基或NR 27 R 28 -C 1-4烷基取代; Ar 4和Ar 5表示苯基; Ar 6表示任选被硝基取代的苯基。
-
公开(公告)号:US20130005769A1
公开(公告)日:2013-01-03
申请号:US13606468
申请日:2012-09-07
申请人: Pierre Henri Storck , Bruno Schoentjes , Arnaud Marcel Pierre Piettre , Philipp Ermert , Virginie Sophie Poncelet , Imre Christian Francis Csoka
发明人: Pierre Henri Storck , Bruno Schoentjes , Arnaud Marcel Pierre Piettre , Philipp Ermert , Virginie Sophie Poncelet , Imre Christian Francis Csoka
IPC分类号: C07D401/14 , A61P35/00 , A61P35/02 , A61K31/4709
CPC分类号: C07D413/14
摘要: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds: wherein n, s, t, R1, R2, R3, R4, R5, X, Y, Q, Z, G, E and D have defined meanings.
摘要翻译: 本发明提供式(I)化合物,其作为p53-MDM2相互作用抑制剂的用途以及包含所述化合物的药物组合物:其中n,s,t,R1,R2,R3,R4,R5,X, Y,Q,Z,G,E和D具有定义的含义。
-
-
-
-